TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: INternational VErapamil SR Trandolapril STudy
Brief Summary: Because blood pressure affects the heart, blood vessels, kidneys, and the entire body, it is important to keep it as normal as possible. There are several different ways to control blood pressure and to prevent or limit the development of heart disease due to high blood pressure. The purpose of this study is to compare two treatments to see how well they work and the difference in their side effects. One treatment includes the use of a calcium antagonist drug (Isoptin sustained release \[SR\] or Verapamil SR). The other treatment excludes the calcium antagonist and may include a non-calcium antagonist drug called a beta blocker (Tenormin or Atenolol). Both treatments may also include medication called angiotensin converting enzyme (ACE) inhibitors and water pills. None of the drugs in this study are experimental, they are all approved by the Food and Drug Administration (FDA).


Options:
A: Arm Label: Glycemia Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: Glycemia Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: BP Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hypertensive Agents | Arm Label: BP Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hypertensive Agents | Arm Label: Lipid Trial: fenofibrate; Type: EXPERIMENTAL; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Arm Label: Lipid Trial: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Intervention Type: DRUG; Name: Anti-hyperglycemic Agents; Assigned to Arm(s): Glycemia Trial: intensive control, Glycemia Trial: standard control | Intervention Type: DRUG; Name: Anti-hypertensive Agents; Assigned to Arm(s): BP Trial: intensive control, BP Trial: standard control | Intervention Type: DRUG; Name: Blinded fenofibrate or placebo plus simvastatin; Assigned to Arm(s): Lipid Trial: fenofibrate, Lipid Trial: placebo
B: Intervention Type: DRUG; Name: Telmisartan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Combination of Telmisartan and Ramipril; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Ramipril; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Verapamil SR/Trandolapril/Hydrochlorothiazide (HCTZ); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Atenolol/HCTZ/Trandolapril; Assigned to Arm(s): N/A
D: Arm Label: SANDS Control Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: SANDS Intervention Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: FDA approved drugs to treat blood pressure and cholesterol | Intervention Type: DRUG; Name: FDA approved drugs to treat blood pressure and cholesterol; Assigned to Arm(s): SANDS Intervention Group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Control Trial Of Mifepristone for Fibroids
Brief Summary: The purpose of this trial is to determine if low-dose mifepristone benefits women with symptomatic fibroids.


Options:
A: Arm Label: Ulipristal acetate (PGL4001) 5mg; Type: EXPERIMENTAL; Interventions: Drug: PGL4001 5 mg | Arm Label: Ulipristal acetate (PGL4001) 10mg; Type: EXPERIMENTAL; Interventions: Drug: PGL4001 10 mg | Intervention Type: DRUG; Name: PGL4001 5 mg; Assigned to Arm(s): Ulipristal acetate (PGL4001) 5mg | Intervention Type: DRUG; Name: PGL4001 10 mg; Assigned to Arm(s): Ulipristal acetate (PGL4001) 10mg
B: Arm Label: Mifepristone; Type: EXPERIMENTAL; Interventions: Drug: Mifepristone | Arm Label: Inert capsule; Type: PLACEBO_COMPARATOR; Interventions: Drug: Inert Capsule | Intervention Type: DRUG; Name: Mifepristone; Assigned to Arm(s): Mifepristone | Intervention Type: DRUG; Name: Inert Capsule; Assigned to Arm(s): Inert capsule
C: Arm Label: ulipristal acetate -20 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: ulipristal acetate 20 mg | Arm Label: ulipristal acetate - 10 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: ulipristal acetate 10 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Pre-ulipristal acetate 10 mg; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Pre-ulipristal acetate 20 mg; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Pre-placebo; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: ulipristal acetate 20 mg; Assigned to Arm(s): ulipristal acetate -20 mg | Intervention Type: DRUG; Name: ulipristal acetate 10 mg; Assigned to Arm(s): ulipristal acetate - 10 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Asoprisnil | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Asoprisnil | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Asoprisnil | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Asoprisnil; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Asoprisnil; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Asoprisnil; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of Iron/Folic Acid Versus Multimicronutrient Versus Folic Acid Supplements During Pregnancy on Mortality, Morbidity, and Complications During Pregnancy, Labor, and Delivery: A Randomized Controlled Trial in China
Brief Summary: The purpose of this study is to determine whether a daily prenatal supplement of iron plus folic acid or a daily prenatal supplement with multiple vitamins and minerals given to women from their first prenatal visit through delivery reduces perinatal mortality compared with a daily prenatal supplement of folic acid alone.


Options:
A: Arm Label: A, 1; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: folic acid | Arm Label: A, 2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: folic acid plus iron | Arm Label: A, 3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: supplements with multiple vitamins and minerals | Intervention Type: DIETARY_SUPPLEMENT; Name: folic acid; Assigned to Arm(s): A, 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: folic acid plus iron; Assigned to Arm(s): A, 2 | Intervention Type: DIETARY_SUPPLEMENT; Name: supplements with multiple vitamins and minerals; Assigned to Arm(s): A, 3
B: Arm Label: Pregnant Women; Type: N/A; Interventions: Drug: Traditional Tablet, Drug: Chewable tablets, Drug: Unflavoured Powder, Drug: Flavoured Powder | Intervention Type: DRUG; Name: Traditional Tablet; Assigned to Arm(s): Pregnant Women | Intervention Type: DRUG; Name: Chewable tablets; Assigned to Arm(s): Pregnant Women | Intervention Type: DRUG; Name: Unflavoured Powder; Assigned to Arm(s): Pregnant Women | Intervention Type: DRUG; Name: Flavoured Powder; Assigned to Arm(s): Pregnant Women
C: Intervention Type: DIETARY_SUPPLEMENT; Name: Daminaide 995 - SuppleFem Sprinkles; Assigned to Arm(s): N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Materna; Assigned to Arm(s): N/A
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Other: Nutritional Counselling and Education | Arm Label: B; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Micronutrient Supplementation without Zinc | Arm Label: C; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Micronutrient Supplementation with Zinc | Intervention Type: DIETARY_SUPPLEMENT; Name: Micronutrient Supplementation without Zinc; Assigned to Arm(s): B | Intervention Type: DIETARY_SUPPLEMENT; Name: Micronutrient Supplementation with Zinc; Assigned to Arm(s): C | Intervention Type: OTHER; Name: Nutritional Counselling and Education; Assigned to Arm(s): A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prevention of Pre-Term Birth by Treatment of Periodontal Disease During Pregnancy - The Smile Study
Brief Summary: The aim of the study is to investigate, in an Australian population of pregnant women, whether the treatment of periodontal disease during pregnancy prevents pre-term birth and other complications of pregnancy. Dental screening and periodontal treatment protocols have been based on standard techniques employed by hygienists that can be readily applied to the general obstetric population.


Options:
A: Arm Label: Periodontal Treatment; Type: EXPERIMENTAL; Interventions: Other: multi-center, randomized, controled periodontal therapy | Intervention Type: OTHER; Name: multi-center, randomized, controled periodontal therapy; Assigned to Arm(s): Periodontal Treatment
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Scaling and root planing | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Scaling and root planing | Intervention Type: PROCEDURE; Name: Scaling and root planing; Assigned to Arm(s): 1, 2
C: Arm Label: Scaling and root planing; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Periodontal scaling and root planing, Procedure: Scaling and root planing | Arm Label: Placebo; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Periodontal scaling and root planing; Assigned to Arm(s): Scaling and root planing | Intervention Type: PROCEDURE; Name: Scaling and root planing; Assigned to Arm(s): Scaling and root planing
D: Intervention Type: PROCEDURE; Name: Treatment of periodontal disease; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: REducing Deaths Due to OXidative Stress The REDOXS© Study
Brief Summary: The purpose of this study is to determine whether providing high dose glutamine and antioxidants to critically ill patients will be associated with improved survival.


Options:
A: Arm Label: Enteral Glutamine; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Enteral Glutamine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Enteral Glutamine; Assigned to Arm(s): Enteral Glutamine | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Glutamine; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Total Parenteral Nutrition with Glutamine | Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Other: Total Parenteral Nutrition without glutamine | Intervention Type: DIETARY_SUPPLEMENT; Name: Total Parenteral Nutrition with Glutamine; Assigned to Arm(s): Glutamine | Intervention Type: OTHER; Name: Total Parenteral Nutrition without glutamine; Assigned to Arm(s): Control
C: Arm Label: alanyl-glutamine; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Dipeptiven | Arm Label: normal saline; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: normal saline | Intervention Type: DIETARY_SUPPLEMENT; Name: Dipeptiven; Assigned to Arm(s): alanyl-glutamine | Intervention Type: DIETARY_SUPPLEMENT; Name: normal saline; Assigned to Arm(s): normal saline
D: Arm Label: Glutamine; Type: EXPERIMENTAL; Interventions: Other: Glutamine | Arm Label: Antioxidants; Type: EXPERIMENTAL; Interventions: Other: Antioxidants | Arm Label: Glutamine + Antioxidants; Type: EXPERIMENTAL; Interventions: Other: Glutamine + Antioxidants | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: OTHER; Name: Glutamine; Assigned to Arm(s): Glutamine | Intervention Type: OTHER; Name: Antioxidants; Assigned to Arm(s): Antioxidants | Intervention Type: OTHER; Name: Glutamine + Antioxidants; Assigned to Arm(s): Glutamine + Antioxidants | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Study Comparing the Incidence of Cardiovascular Events Between High-dose ARB Monotherapy and Combination Therapy With ARB and Calcium Channel Blocker in Japanese Elderly Hypertensive Patients at High Cardiovascular Risk
Brief Summary: The purpose of this study is to investigate whether high-dose angiotensin II receptor blocker (ARB) monotherapy or combination therapy with ARB and calcium channel blockers is more effective in reducing the incidence of cardiovascular events in Japanese elderly high-risk hypertensive patients not adequately controlled by standard dose ARB alone.


Options:
A: Intervention Type: DRUG; Name: Inhibitors, ACE; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: amlodipine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: lisinopril; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: doxazosin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: chlorthalidone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: pravastatin; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Delapril, Delapril-Manidipine Fixed combination; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olmesartan medoxomil | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Calcium channel blockers (amlodipine, azelnidipine) | Intervention Type: DRUG; Name: Olmesartan medoxomil; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Calcium channel blockers (amlodipine, azelnidipine); Assigned to Arm(s): 2
D: Arm Label: Valsartan; Type: ACTIVE_COMPARATOR; Interventions: Drug: Valsartan | Arm Label: Amlodipine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amlodipine | Intervention Type: DRUG; Name: Valsartan; Assigned to Arm(s): Valsartan | Intervention Type: DRUG; Name: Amlodipine; Assigned to Arm(s): Amlodipine

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Study Comparing the Incidence of Cardiovascular Events Between High-dose ARB Monotherapy and Combination Therapy With ARB and Calcium Channel Blocker in Japanese Elderly Hypertensive Patients at High Cardiovascular Risk
Brief Summary: The purpose of this study is to investigate whether high-dose angiotensin II receptor blocker (ARB) monotherapy or combination therapy with ARB and calcium channel blockers is more effective in reducing the incidence of cardiovascular events in Japanese elderly high-risk hypertensive patients not adequately controlled by standard dose ARB alone.


Options:
A: Arm Label: Blood pressure; Type: PLACEBO_COMPARATOR; Interventions: Drug: Perindopril-indapamide | Arm Label: Glucose control; Type: OTHER; Interventions: Drug: Gliclazide MR-based glucose lowering | Intervention Type: DRUG; Name: Perindopril-indapamide; Assigned to Arm(s): Blood pressure | Intervention Type: DRUG; Name: Gliclazide MR-based glucose lowering; Assigned to Arm(s): Glucose control
B: Arm Label: Nurse administered; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse administered | Arm Label: Nurse & BP monitor; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse administered, Device: BP Monitor | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Home BP Monitor; Type: EXPERIMENTAL; Interventions: Device: BP Monitor | Intervention Type: BEHAVIORAL; Name: Nurse administered; Assigned to Arm(s): Nurse & BP monitor, Nurse administered | Intervention Type: DEVICE; Name: BP Monitor; Assigned to Arm(s): Home BP Monitor, Nurse & BP monitor
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olmesartan medoxomil | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Calcium channel blockers (amlodipine, azelnidipine) | Intervention Type: DRUG; Name: Olmesartan medoxomil; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Calcium channel blockers (amlodipine, azelnidipine); Assigned to Arm(s): 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Olmesartan medoxomil | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Tablets | Intervention Type: DRUG; Name: Olmesartan medoxomil; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo Tablets; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective, Randomized Study on Two Parallel Groups Comparing Dopexamine and Norepinephrine in Combination to Epinephrine Alone on Systemic and Pulmonary Hemodynamics, Gastric Mucosal Perfusion, and Oxidative Stress in Septic Shock
Brief Summary: In septic shock, when volume resuscitation fails to restore mean arterial pressure, catecholamines such as dopamine, dobutamine, epinephrine, or norepinephrine are used, either alone or in combination. Although they allow hemodynamic success to be obtained, they can leave some regional blood flows impaired, especially the hepatosplanchnic perfusion, which contributes to multiple organ failure.

Dopexamine is a structural and synthetic analog of dopamine that exerts systemic and gut vasodilation and stimulates cardiac contraction. In experimental models, dopexamine has been shown to exert anti-inflammatory properties and to protect the hepatic ultra structure. The combination of dopexamine and norepinephrine could therefore constitute an interesting alternative in treating septic shock patients. This study will test the efficacy (on gastric mucosal blood flow, hepatic damage and oxidative stress) and safety of the combination of dopexamine and norepinephrine (compared to those of epinephrine alone) in the treatment of patients with septic shock.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Terlipressin | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Vasopressin | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Norepinephrine | Intervention Type: DRUG; Name: Terlipressin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Vasopressin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Norepinephrine; Assigned to Arm(s): 3
B: Arm Label: Angiotensin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Angiotensin II | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Angiotensin II | Intervention Type: DRUG; Name: Angiotensin II; Assigned to Arm(s): Angiotensin, Control
C: Intervention Type: DRUG; Name: Dopexamine and norepinephrine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Epinephrine; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Early Goal Directed Therapy (EGDT) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: Protocolized Standard Care (PSC) | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Usual Care (UC) | Intervention Type: PROCEDURE; Name: Early Goal Directed Therapy (EGDT); Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Protocolized Standard Care (PSC); Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: Usual Care (UC); Assigned to Arm(s): 3

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Mixed Hyperlipidemia
Brief Summary: The Torcetrapib project was terminated on December 2, 2006 due to safety findings.

To look at ultrasound images taken in the carotid arteries and to look at various lipids in the blood of people with mixed hyperlipidemia


Options:
A: Intervention Type: DRUG; Name: torcetrapib/atorvastatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: torcetrapib/atorvastatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: torcetrapib/atorvastatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): N/A
D: Arm Label: Rosuvastatin; Type: EXPERIMENTAL; Interventions: Drug: Rosuvastatin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): Rosuvastatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Mixed Hyperlipidemia
Brief Summary: The Torcetrapib project was terminated on December 2, 2006 due to safety findings.

To look at ultrasound images taken in the carotid arteries and to look at various lipids in the blood of people with mixed hyperlipidemia


Options:
A: Intervention Type: DRUG; Name: aspirin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: lovastatin; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: torcetrapib/atorvastatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): N/A
D: Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Drug: ASA, Drug: Clopidogrel 75mg | Arm Label: Apixaban group; Type: EXPERIMENTAL; Interventions: Drug: Apixaban, Drug: ASA | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban group | Intervention Type: DRUG; Name: ASA; Assigned to Arm(s): Apixaban group, Control group | Intervention Type: DRUG; Name: Clopidogrel 75mg; Assigned to Arm(s): Control group

Answer: C